1111637-91-2 Usage
Uses
Used in Organic Synthesis:
3-Methyl-5-(4,4,5,5-tetraMethyl-[1,3,2]dioxaborolan-2-yl)-pyridin-2-ylamine is used as a building block in organic synthesis for the creation of complex organic molecules. Its unique structure allows for the formation of new chemical bonds and the synthesis of a wide range of compounds.
Used in Pharmaceutical Research:
In the pharmaceutical industry, 3-Methyl-5-(4,4,5,5-tetraMethyl-[1,3,2]dioxaborolan-2-yl)-pyridin-2-ylamine is utilized as a key component in the development of novel drugs. Its potential applications include the synthesis of new therapeutic agents and the enhancement of existing drug properties.
Used as a Ligand in Coordination Chemistry:
3-Methyl-5-(4,4,5,5-tetraMethyl-[1,3,2]dioxaborolan-2-yl)-pyridin-2-ylamine serves as a ligand in coordination chemistry, playing a crucial role in the formation of metal complexes. These complexes have potential applications in various fields, including catalysis, materials science, and medicinal chemistry.
Used in the Development of New Materials:
This chemical compound contributes to the development of new materials with unique properties. Its incorporation into various materials can lead to improved performance and novel applications in different industries.
Used in Agricultural Chemicals:
3-Methyl-5-(4,4,5,5-tetraMethyl-[1,3,2]dioxaborolan-2-yl)-pyridin-2-ylamine may have potential uses in the field of agricultural chemicals, where it could be employed as an active ingredient in the development of new pesticides or other agrochemical products.
Used as an Intermediate in Specialty Chemicals Production:
As an intermediate, 3-Methyl-5-(4,4,5,5-tetraMethyl-[1,3,2]dioxaborolan-2-yl)-pyridin-2-ylamine is involved in the production of specialty chemicals. Its presence in the synthesis process allows for the creation of high-value chemicals used in various applications, such as fragrances, dyes, and other specialty products.
Check Digit Verification of cas no
The CAS Registry Mumber 1111637-91-2 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,1,1,1,6,3 and 7 respectively; the second part has 2 digits, 9 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 1111637-91:
(9*1)+(8*1)+(7*1)+(6*1)+(5*6)+(4*3)+(3*7)+(2*9)+(1*1)=112
112 % 10 = 2
So 1111637-91-2 is a valid CAS Registry Number.
1111637-91-2Relevant academic research and scientific papers
Small molecule compound
-
Paragraph 0549-0550; 0551-0552, (2020/01/12)
The invention provides a small molecular compound, The small molecular compound is characterized by having a structure as shown in the following molecular general formula, wherein X1 and X2 are selected from carbon or nitrogen, G1 is a carbon ring or a heterocyclic ring with aromaticity, any one or more hydrogen atoms on the G1 ring are substituted by R1, wherein R1 is selected from nitrogen-containing groups. The small molecule compound can be used as an efficient and specific JAK kinase inhibitor, especially a Tyk2 inhibitor, and/or a JAK1 inhibitor, and/or a JAK1/Tyk2 dual inhibitor, or a Tyk2/JAK1 dual inhibitor or a Tyk2/Jak2 dual inhibitor.
COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES
-
Page/Page column 71; 94; 95, (2014/06/11)
The present invention provides compounds of formula I: [INSERT FORMULA HERE] or a pharmaceutically acceptable salt, tautomer, or stereoisomer, thereof, wherein the variables are as defined herein. The present invention further provides pharmaceutical compositions comprising such compounds and methods of using such compounds for treating, preventing, inhibiting, ameliorating, or eradicating the pathology and/or symptomology of a disease caused by a Plasmodium parasite, such as malaria.
PYRIDO[3,2-d]PYRIMIDINE PI3K DELTA INHIBITOR COMPOUNDS AND METHODS OF USE
-
Page/Page column 66, (2011/09/16)
Formula I compounds, including stereoisomers, geometric isomers, tautomers, metabolites and pharmaceutically acceptable salts thereof, are useful for inhibiting the delta isoform of PI3K, and for treating disorders mediated by lipid kinases such as inflammation, immunological disorders, and cancer. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.
PYRAZOLE COMPOUNDS
-
Page/Page column 63-64, (2009/03/07)
The present invention is directed to compounds of Formula (I) and to pharmaceutically acceptable salts thereof, their synthesis, and their use as Raf inhibitors.
